Oxygenta Pharmaceutical (524636) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
20 Nov, 2025Executive summary
Un-audited financial results for the quarter and half-year ended September 30, 2024, were approved and reviewed by the Board and statutory auditors.
The company operates solely in the manufacturing of pharmaceutical products.
Financial highlights
Total income from operations for Q2 FY25 was ₹1,475.45 lakhs, up from ₹1,307.71 lakhs in Q2 FY24.
Net loss for Q2 FY25 stood at ₹285.39 lakhs, compared to a net loss of ₹316.00 lakhs in Q2 FY24.
Loss before tax for Q2 FY25 was ₹277.34 lakhs, an improvement from ₹317.99 lakhs loss in Q2 FY24.
EPS (basic) for Q2 FY25 was (₹0.81), compared to (₹0.87) in Q2 FY24.
Outlook and guidance
The company is prioritizing compliance and transparency, especially regarding statutory obligations and MSME creditor identification.
Latest events from Oxygenta Pharmaceutical
- FY26 revenue rose but net loss deepened; board changes and compliance focus highlighted.524636
Q4 25/2623 May 2026 - Revenue rose but net losses widened in Q3 FY26; compliance and creditor processes are ongoing.524636Q3 25/264 Feb 2026
- Revenue surged in FY25, but losses deepened amid compliance and reporting challenges.524636Q4 24/2520 Nov 2025
- Q3 FY25 revenue surged, but losses deepened and compliance issues remain under review.524636Q3 24/2520 Nov 2025
- Q1 FY25 revenue up, net loss narrows, equity raised via share allotment; compliance issues persist.524636Q1 24/2520 Nov 2025
- Revenue rose modestly, but losses widened; new CFO appointed and compliance efforts ongoing.524636Q2 25/267 Nov 2025
- Q1 FY26 saw higher revenue but a deeper net loss, with new auditor and compliance appointments.524636Q1 25/2619 Aug 2025